

Remarks

Claims 5-10 have been withdrawn in response to this restriction requirement. Applicants reserve their right to file divisional(s) directed to these withdrawn claims.

The Examiner alleges that a Restriction is required under 35 U.S.C. 121 and 372 to the following Groups:

Group I, claim(s) 1-4, drawn to a method for identifying an agent.

Group II, claim(s) 5, drawn to a kit for identifying an agent.

Group III, claim(s) 6-9, drawn to agents and a pharmaceutical composition.

Group IV, claim(s) 10, drawn to a method of treatment of autoimmune-related diseases or allergic diseases.

Applicants elect Group I without traverse.

Further, the Examiner alleges that this application contains claims directed to more than one species of the generic invention. The Examiner requests that if Group I is elected, the following species election must be made from the following:

- i. IL-4
- ii. IL-10
- iii. IFN- γ

Applicants elect IL-4 for examination purposes without traverse. Claims 1-4 are readable on the elected species.

In view of the remarks and the amendments, further and favorable consideration of the present application and the allowance of all pending claims are respectfully requested. The Examiner is also invited to contact the undersigned should the Examiner believe that such contact would expedite prosecution of the present application.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: 11/16/05